Actively Recruiting
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Led by The First Affiliated Hospital of Soochow University · Updated on 2024-04-26
146
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Soochow University
Lead Sponsor
C
Children's Hospital of Soochow University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are: Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL. Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.
CONDITIONS
Official Title
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with acute T cell lymphoblastic leukemia
- Available minimal residual disease parameters assessed by flow cytometry and/or quantitative polymerase chain reaction
- Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
- Signed informed consent and ability to comply with study and follow-up procedures
You will not qualify if you...
- Presence of other malignancies
- Failure to acquire a suitable unrelated cord blood unit
- Previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation, or chimeric antigen receptor T cell therapy
- Uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation
- Severe organ dysfunction
- Pregnancy or lactation period
- Any condition deemed unsuitable for the trial by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
Y
Yang XU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here